Bio-Rad Laboratories, Inc.
General ticker "BIO-B" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $8.8B (TTM average)
Bio-Rad Laboratories, Inc. follows the US Stock Market performance with the rate: 16.9%.
Estimated limits based on current volatility of 0.0%: low 250.08$, high 250.08$
Factors to consider:
- US accounted for 40.6% of revenue in the fiscal year ended 2024-12-31
Short-term BIO-B quotes
Long-term BIO-B plot
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2,802.20MM | $2,671.20MM | $2,566.50MM |
| Operating Expenses | $2,319.60MM | $2,333.40MM | $2,297.50MM |
| Operating Income | $482.60MM | $337.80MM | $269.00MM |
| Non-Operating Income | $-5,186.80MM | $-1,187.90MM | $-2,611.50MM |
| Interest Expense | $38.10MM | $49.40MM | $48.90MM |
| R&D Expense | $256.90MM | $247.40MM | $295.90MM |
| Income(Loss) | $-4,704.20MM | $-850.10MM | $-2,342.50MM |
| Taxes | $-1,076.70MM | $-212.80MM | $-498.30MM |
| Profit(Loss)* | $-3,627.53MM | $-637.32MM | $-1,844.20MM |
| Stockholders Equity | $9,615.25MM | $8,741.20MM | $6,569.30MM |
| Inventory | $719.32MM | $780.52MM | $0.00MM |
| Assets | $13,501.67MM | $12,299.10MM | $9,364.10MM |
| Operating Cash Flow | $194.45MM | $374.94MM | $455.20MM |
| Capital expenditure | $114.16MM | $156.68MM | $189.00MM |
| Investing Cash Flow | $-1,207.59MM | $20.21MM | $-160.20MM |
| Financing Cash Flow | $973.58MM | $-425.65MM | $-218.80MM |
| Earnings Per Share** | $-121.79 | $-21.82 | $-65.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.